Want to join the conversation?
Pharmaceutical company $CVS posted lower 1Q16 net earnings of 6.1% vs. 1Q15, hurt by higher interest expense of $149MM and $61MM of acquisition-related integration costs. This was partially offset by higher operating profit. Diluted EPS was $1.04 for the quarter. Revenues rose 18.9% vs. 1Q15, helped by increases in the company's segment revenues.
Late realization to $T that it cannot compete in the unlimited data market with its existing plans! Its newly launched plans seem more reasonable.